Viewing nowCombinationGlicetamet XR Extended-Release Tablets 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.

MFDS item code 202201953 · Approved 2022.05.11 · Insurance code 657308730
Improvement of glycemic control in patients with type 2 diabetes
This medication is used to assist patients with type 2 diabetes in managing their blood sugar levels through the combination of sitagliptin and metformin. When taken alongside dietary management and exercise, it helps maintain blood sugar levels effectively. Therefore, this medication is an effective treatment option for individuals experiencing difficulties with blood sugar control.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which this medicine was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablets once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no previous experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Use This Medicine). 2. Patients treated with metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients who were taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily may start at a dose of 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, provided that the following dosage adjustments are made. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Medicine).
This medication contains two ingredients, sitagliptin and metformin, and is used for the treatment of type 2 diabetes. First, sitagliptin can rarely cause severe allergic reactions, so if symptoms such as skin rashes, difficulty breathing, or swelling of the face or neck occur, use should be discontinued immediately. Additionally, there is a risk of acute pancreatitis, which involves inflammation of the pancreas, so if severe abdominal pain or vomiting occurs, immediate medical attention is required. Metformin can cause lactic acidosis, a rare but life-threatening metabolic disorder, and should not be used in patients with reduced kidney function or poor liver function. It should also be avoided in acute conditions that can affect kidney function, such as dehydration, severe infections, heart attack, or shock. This medication should not be used in patients with moderate to severe impairment of kidney function, those with acute heart failure, patients scheduled for tests using iodine contrast agents, individuals with type 1 diabetes, or pregnant or breastfeeding women. Caution should be taken when administering this medication to patients with irregular eating habits, insufficient food intake, or those engaging in vigorous exercise, as interactions with other medications may occur. During treatment, signs of hypoglycemia should be monitored, especially when used with insulin or sulfonylureas, as the risk of hypoglycemia may increase. Regular monitoring of kidney function and blood tests is necessary, and supplementation may be needed if vitamin B12 levels decrease. Excessive alcohol consumption can increase the risk of lactic acidosis, so it is advised to avoid drinking alcohol while taking this medication. In cases of surgery, medication should be discontinued 48 hours before the procedure, and should only be resumed once kidney function has been confirmed to be normal after surgery. Finally, this medication is not recommended for children (under 18 years old) and pregnant women due to unclear safety profiles. It is important to immediately report any unusual symptoms or discomfort to medical personnel while taking this medication.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to protect it from air and moisture, and it is important to maintain a storage temperature between 1 to 30 degrees Celsius. Storing it this way will help preserve the medication's efficacy and prevent degradation.
Light green, oval, double-convex extended-release film-coated tablet
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.